EUVIMEDEUVIMED entdecken
Open Access

Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database

Xianyan Yan iD, Hunong Xiang, Jingzhong Ou, Li Pan, Xiaoyan Wang, Liping Liu, Yuanling Zhou, Yan Li, Ronghua Zhang, Yanping Wu

Hospital Pharmacy · 2026-12 · 61 (6) · 582-590

DOI: 10.1177/00185787261433433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hospital Pharmacy, online erschienen am 17.04.2026. Verfasst von Xianyan Yan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Xindu District People's Hospital of Chengdu, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the adverse event profile and potential safety signals associated with glyburide use during pregnancy using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods

Data from FAERS (Q1 2015-Q1 2025) were analyzed. Pregnant cases and glyburide exposures were identified using standardized MedDRA terminology. Signal detection was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms.

Results

A total of 284 712 pregnant women were included, among whom 164 used glyburide. Seventeen positive safety signals were detected. Hypoglycaemia neonatal, congenital anomaly in offspring, and maternal hypoglycaemia were consistent with drug labeling and previous reports. Additional newly identified signals included caesarean section, placenta praevia, amniotic fluid volume decreased, blood creatinine increased, hypoxia, metabolic acidosis, umbilical cord abnormality, and others. At the system organ class (SOC) level, positive signals were observed for metabolism and nutrition disorders, endocrine disorders, and pregnancy, puerperium and perinatal conditions.

Conclusion

This real-world FAERS-based analysis suggests that glyburide use during pregnancy may be associated with various adverse metabolic and pregnancy-related outcomes. Caution is warranted when prescribing glyburide for patients with HIP, with particular attention to monitoring placental function and neonatal glucose levels. Further prospective studies are needed to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

FAERSadverse eventsglyburidehyperglycemia in pregnancysignal detection

Autor:innen und Institutionen

  • Xindu District People's Hospital of Chengdu, China.
  • Sichuan University, Chengdu, China.

ORCID-Profile: Xianyan Yan

Zitieren

APA

Yan, X., Xiang, H., Ou, J., Pan, L., Wang, X., Liu, L., Zhou, Y., Li, Y., Zhang, R., & Wu, Y. (2026). Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database. Hospital Pharmacy, 61(6), 582-590. https://doi.org/10.1177/00185787261433433

Vancouver

Yan X, Xiang H, Ou J, Pan L, Wang X, Liu L, et al. Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database. Hospital Pharmacy. 2026;61(6):582-590. doi:10.1177/00185787261433433

BibTeX
@article{Yan2026,
  author = {Yan, Xianyan and Xiang, Hunong and Ou, Jingzhong and Pan, Li and Wang, Xiaoyan and Liu, Liping and Zhou, Yuanling and Li, Yan and Zhang, Ronghua and Wu, Yanping},
  title = {Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database},
  journal = {Hospital Pharmacy},
  year = {2026},
  volume = {61},
  number = {6},
  pages = {582--590},
  doi = {10.1177/00185787261433433}
}
Kostenlos starten →